RHEUMATOLOGY INTERNATIONAL-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2020-08-25 韩杰

可以买到相关风湿免疫相关期刊

150 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2019-10-25 147612bem32暂无昵称

求经验求分享

184 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2019-09-28 1472832bm90暂无昵称

请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表:
接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错

wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错

174 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2019-05-29 wintercome

接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错

178 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2019-01-17 ahslyylilei

请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表:
计算了接受率，大概25%左右，现在很难投了，大家谨慎

482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎

212 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2019-01-15 758332407

审稿速度:1.0 | 投稿命中率:50.0
经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够

111 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2018-12-09 482809040_72850569

审稿速度:6.0 | 投稿命中率:25.0
经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎

224 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2018-05-11 merryfox

审稿速度:2.0 | 投稿命中率:50.0
经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。

261 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2018-03-06 121c4f01m96(暂无昵称)

请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了

437 0

[GetPortalCommentsPageByObjectIdResponse(id=813017, encodeId=fa4e81301ed9, content=可以买到相关风湿免疫相关期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aa05412020, createdName=韩杰, createdTime=Tue Aug 25 11:31:32 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578736, encodeId=ca1c5e873621, content=求经验求分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577074, encodeId=f15c5e7074db, content=请问这个期刊有共同第一作者么wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=wintercome 2019-05-29 00:00:00 发表: 接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea805195919, createdName=1472832bm90暂无昵称, createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571625, encodeId=61ec5e16253b, content=接受了，第一次投，casebased review，感觉比较好中，前后花的时间也就两个月吧，效率不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b731691917, createdName=wintercome, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565709, encodeId=fe44565e0958, content=请问你的中了是么482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=482809040_72850569 2018-12-09 22:17:00 发表: 计算了接受率，大概25%左右，现在很难投了，大家谨慎, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/151fd5f60fa204acdeb19399a3621e8a.jpg, createdBy=67e41927916, createdName=ahslyylilei, createdTime=Thu Jan 17 00:00:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=565608, encodeId=885556560802, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2018年12月31日投稿，1月4日with editor，1月14日拒稿，没送审，编辑觉得文章创新性不够, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=305e1523967, createdName=758332407, createdTime=Tue Jan 15 14:18:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564237, encodeId=b18656423ea8, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：计算了接受率，大概25%左右，现在很难投了，大家谨慎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80bd2403276, createdName=482809040_72850569, createdTime=Sun Dec 09 22:17:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555960, encodeId=b9ad5559602f, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：去年初投了一篇关于疾病基因方面的研究，2个月后给了修改意见，修改后一周内就决定接收了。去年底投了另一篇关于另一种疾病基因的研究，2个月内收到拒绝回信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=261, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53fd2036979, createdName=merryfox, createdTime=Fri May 11 09:09:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553352, encodeId=9ad355335281, content=请问投稿的时候到suggest reviewers这一步时如何找评审专家填进去.急.谢谢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=437, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553351, encodeId=aebc553351eb, content=请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表:: 可以黄庆 2018-01-31 00:00:00 发表: 可以, beContent=黄庆 2018-01-31 发表:: 可以, objectType=tool_impact_factor, channel=null, level=null, likeNumber=279, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13462280621, createdName=121c4f01m96(暂无昵称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]

2018-03-06 121c4f01m96(暂无昵称)

请问投稿的时候到suggest reviwers这一步怎么找评审专家来填.急.谢谢黄庆 2018-01-31 发表::
可以黄庆 2018-01-31 00:00:00 发表:
可以

黄庆 2018-01-31 发表:: 可以

279 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务